Newsletters

[Nature Medicine] Scientists conducted the HEAL-CHF trial, in which patients with advanced heart failure with reduced ejection fraction were randomized to receive intramyocardial injections of allogeneic hiPSC-derived cardiomyocytes or were uninjected.

[ACS Nano] Researchers developed KINESIS (K⁺-Ion Nano-Electrode Selective Interface System), a potassium-selective nanoelectrode platform that enables label-free, single-cell monitoring of K⁺ dynamics in hiPSC-derived cardiomyocytes for cardiotoxicity testing and disease modeling.

[Cardiovascular Research] Investigators showed that Ffar4 protects cardiac muscle cells from ischemic injury by preserving mitochondrial function and cGMP signaling, helping prevent cardiac dysfunction after ischemia-reperfusion.

[Journal of Molecular and Cellular Cardiology] The authors showed that protein phosphatase 2A (PP2A)cα promotes cardiomyocyte proliferation and heart regeneration by activating Hippo–YAP signaling, revealing a potential therapeutic target for cardiac repair after myocardial infarction.

[Biofabrication] Scientists developed a one-step coaxial bioprinting strategy to create aligned, vascularized 3D skeletal muscle constructs, advancing muscle regeneration, disease modeling, and drug screening.

[ACS Applied Materials & Interfaces] Investigators developed a myogenic platform that provides a comprehensive set of bioactive cues, including bioelectrical cues that can be delivered wirelessly, to promote skeletal muscle development.

[Angiogenesis] Researchers developed a robust co-culture system of HUVECs and smooth muscle cells to generate stable vascular networks capable of maintaining tissue viability over extended periods.

[Bone Research] Scientists examine how biomolecular condensates and liquid-liquid phase separation-related mechanisms have been implicated in osteoporosis, osteoarthritis, skeletal muscle atrophy, bone and soft tissue sarcomas, and neuromusculoskeletal diseases.

[Precision BioSciences, Inc.] Precision BioSciences, Inc. announced the dosing of the first patient in August in the Phase I/II FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD).

[Cancer Gene Therapy] Researchers discovered a pronounced overexpression of NAT10 in prostate cancer tissues and cell lines, which correlated with enhanced cellular proliferation, migration, invasion, and overall tumor growth.

[Oncogenesis] Scientists elucidated that BCL-xL is the major pro-survival protein in prostate cancer cell lines after docetaxel treatment, which can be reverted using BH3 mimetics or PROTAC strategies against this protein.

[University of Mississippi Medical Center] University of Mississippi Medical Center research to study the mechanisms of prostate cancer bone metastasis and evaluate new therapies has gained nearly $2.6 million in funding from the National Cancer Institute.